PD-1/PD-L1在三阴性乳腺癌中的研究进展

摘要
图/表
参考文献(32)
相关文章 (3)

全文: PDF (957 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要免疫治疗作为最热门的研究领域之一，诸多临床研究中心在肿瘤药物试验中证实其疗效显著。程序性死亡配体1（PD-L1）是一种参与免疫抑制通路的分子，在较多实体肿瘤细胞及其周围T淋巴细胞表面表达显著，能与其程序性死亡受体1（PD-1）结合，抑制肿瘤组织周围的免疫微环境，促进肿瘤细胞的恶化。三阴性乳腺癌（TNBC），作为乳腺癌的一种亚型，对目前乳腺癌治疗手段均不敏感，患者预后及生活质量较差。本文通过对TNBC中PD-1/PD-L1的表达及相关抑制药物临床试验的疗效进展进行阐述，为制订TNBC患者的个体化治疗方案提供新思路。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	范钰钱震苏勤军李甜甜刘斌▲

关键词 ：程序性死亡受体1, 程序性死亡配体1, 三阴性乳腺癌, 进展

Abstract：Immunotherapy is one of the most popular research fields, and has proved to be effective by many clinical research centers in tumor drug trials. Program-med death receptor ligand 1 (PD-L1) is a molecule involved in immunosuppression pathway, and express in more solid tumor cells and the peripheral T lymphocyte significantly on the surface. It can combine with the programmed death receptor 1 (PD-1), inhibit the immune micro-environment around the tumor tissue, promote the deterioration of the tumor cells. Triple-negative breast cancer(TNBC), as a sub-type of breast cancer, is not sensitive to breast cancer treatment, the prognosis and life quality of patients are poor. This paper elaborates the progress in clinical trials of PD-1/PD-L1 expression and related inhibitory drugs in TNBC, and provides new ideas for the treatment of individual patients with TNBC.

Key words： Programmed death receptor 1 Programmed death ligand 1 Triple-negative breast cancer Progress

通讯作者: ▲通讯作者

引用本文:

范钰钱震苏勤军李甜甜刘斌▲. PD-1/PD-L1在三阴性乳腺癌中的研究进展[J]. 中国医药导报, 2017, 14(33): 51-54,63.
FAN Yu QIAN Zhen SU Qinjun LI Tiantian LIU Bin▲. Advances in the study of PD-1/PD-L1 in triple-negative breast cancer. 中国医药导报, 2017, 14(33): 51-54,63.

链接本文:

http://www.yiyaodaobao.com.cn/CN/ 或 http://www.yiyaodaobao.com.cn/CN/Y2017/V14/I33/51

[1] Gluz O，Liedtke C，Gottschalk N，et al. Triple-negative breast cancer-current status and future directions [J]. Ann Oncol，2009，20（12）：1913-1927.
[2] Millar EKA，Graham PH，O'Toole SA，et al. Prediction of local recurrence，distant metastases，and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel [J]. J Clin Oncol，2009，27（28）：4701-4708.
[3] Voduc KD，Cheang MC，Tyldesley S，et al. Breast cancer subtypes and the risk of local and regional relapse [J]. J Clin Oncol，2010，28（10）：1684-1691.
[4] 母予馨，李青.三阴性乳腺癌内科治疗现状及展望[J].癌症进展，2016，14（12）：1199-1202.
[5] 许宇媚，杨芳，管晓翔，等.三阴性乳腺癌异质性的研究进展[J].癌症进展，2015，13（5）：458-461.
[6] Brahmer JR，Tykodi SS，Chow LQM，et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer [J]. N Engl J Med，2012，366（26）：2455-2465.
[7] Okazaki T，Honjo T. The PD-1/PD-L1 pathway in immunological tolerance [J]. Trends Immunol，2006，27（4）：195-201.
[8] Sun H，Sun C，Xiao W. Expression regulation of coinhibitory molecules on human natural killer cells in response to cytokine stimulations [J]. Cytokine，2014，65（1）：33-41.
[9] Francisco LM，Sage PT，Sharpe AH. The PD-1 pathway in tolerance and autoimmunity [J]. Immunol Rev，2010，236（1）：219-242.
[10] He J，Hu Y，Hu M，et al. Development of PD-1/PD-L1 pathway in tumor immune microenvironment and treatment for non-small cell lung cancer [J]. Sci Rep，2015， 5：13110. Published online 2015 Aug 17. DOI：10.1038/srep13110.
[11] Pedoeem A，Azoulay-Alfaguter I，Strazza M，et al. Programmed death-1 pathway in cancer and autoimmunity [J]. Clin Immunol，2014，153（1）：145-152.
[12] Park HJ， Kusnadi A，Lee EJ，et al. Tumor-infiltrating regulatory T cells delineated by upregulation of PD-1 and inhibitory receptors [J]. Cell Immunol，2012，278（1）：76-83.
[13] Tumeh PC，Harview CL，Yearley JH，et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance [J]. Nature，2014，515（7528）：568-571. DOI：10. 1038/nature13954.
[14] 徐程，华宏金，陈天羽，等.PD-1/PD-L1通路在非小细胞肺癌中的研究进展[J].中华病理学杂志，2016，45（9）：663-666.
[15] Pin W，Dang W，Li J，et al. PD-L1 and Survival in Solid Tumors：A Meta-Analysis [J]. PLoS One. 2015，10（6）：e0131403. DOI.org/10.1371/journal.pone.0131403.
[16] Ohigashi Y，Sho M，Yamada Y，et al. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer [J]. Clin Cancer Res，2005，11（8）：2947-2953.
[17] Xu F，Xu L，Wang Q，et al. Clinicopathological and prognostic value of programmed death ligand-1（PD-L1）in renal cell carcinoma：a meta-analysis [J]. Int J Clin Exp Med，2015，8（9）：14595-14603.
[18] Li X，Li M，Lian Z，et al. Prognostic role of programmed death ligand-1 expression in breast cancer：a systematic review and meta-analysis [J]. Target Oncol，2016，11（6）：753-761.
[19] Guo Y，Yu P，Liu Z，et al. Prognostic and clinicopathological value of programmed death ligand-1 in breast cancer：a meta-analysis [J]. PloS One，2016，11（5）：e0156323.
DOI.org/10.1371/journal.pone.0156323.
[20] Sendur M，Tulbah A，Mohammed S，et al. Expression of PD-L1 in breast cancer patients is strongly associated with ghproliferative Ki-67 expressing tumor cells [J]. Int J Cancer，2007，121（4）：751-758.
[21] Sendur MA，Aksoy S，Demirci S，et al. Can targeted programmed death-1 antibody be a new treatment approach in breast cancer [J]. J BUON，2014，19（2）：584-584.
[22] Li X，Wetherilt CS，Krishnamurti U，et al. Stromal PD-L1 expression is associated with better disease-free survival in triple-negative breast cancer [J]. Am J Clin Pathol，2016，146（4）：496-502.
[23] Beckers RK，Selinger CI，Vilain R，et al. Programmed death ligand 1 expression in triple‐negative breast cancer is associated with tumour‐infiltrating lymphocytes and improved outcome [J]. Histopathology，2016，69（1）：25-34.
[24] Mittendorf EA，Philips AV，Meric-Bernstam F，et al. PD-L1 expression in triple-negative breast cancer [J]. Cancer Immunol Res，2014，2（4）：361-370.
[25] Hu X，Huang W，Fan M. Emerging therapies for breast cancer [J]. J Hematol Oncol，2017，10（1）：98.
[26] Xu F，Feng G，Zhao H，et al. Clinicopathologic Significance and Prognostic Value of B7 Homolog 1 in Gastric Cancer：A Systematic Review and Meta-Analysis [J]. Medicine，2015，94（43）：e1911.DOI：10.1097/MD.00000000000 01911.
[27] Lehmann BD，Bauer JA，Chen X，et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies[J].J Clin Invest，2011，121（7）：2750-2767.
[28] 李毅斌，胡喜钢，汪森明.基于检查点阻断抗体的肿瘤靶向免疫治疗研究进展[J].广东医学，2015，36（3），484-487.
[29] Nanda R，Chow LQ，Dees E，et al. Pembrolizumab in patients with advanced triple-negative breast cancer：phase Ib KEYNOTE-012 study [J]. J Clin Oncol，2016，34（21）：2460-2467.
[30] Rugo HS，Delord JP，Im SA，et al. Abstract S5-07：Preliminary efficacy and safety of pembrolizumab（MK-3475）in patients with PD-L1-positive，estrogen receptor-positive（ER+）/HER2-negative advanced breast cancer enrolled in KEYNOTE-028[DB/OL]. SABCS，2015：s05-07.DOI：10.1158/1538-7445.SABCS15-S5-07 Published February 2016.
[31] Adams S，Diamond J，Hamilton E，et al. Safety and clinical activity of atezolizumab（anti-PDL1）in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer[C]//Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium.2015：8-12.DOI：10.1158/1538-7445.SABCS15-P2-11-06 Published February 2016.
[32] Dirix LY，Takacs I，Nikolinakos P，et al. Avelumab（MSB 0010718C），an anti-PD-L1 antibody，in patients with locally advanced or metastatic breast cancer：A phase b JAVELIN solid tumor trial.[DB/OL].SABCS，2015：AbstrS1-04.DOI：http：//dx.doi.org/10.1016/S0959-8049（16）31447-2.